Comparison ASP of Remicade vs biosimilars in the U.S. Q3 2020
As of Q3 2020, the average sales price (ASP) of autoimmune disease drug Remicade was around 483 U.S. dollars, compared to 457 U.S. dollars for biosimilar Renflexis. This statistic illustrates a comparison of the ASP of Remicade vs biosimilars in the United States.